Predicting Arterial Thrombotic Events Following Peripheral Revascularization Using Objective Viscoelastic Data.

graft thrombosis peripheral artery disease personalized medicine platelet aggregation thromboelastography thromboprophylaxis

Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
03 01 2023
Historique:
pubmed: 25 12 2022
medline: 6 1 2023
entrez: 24 12 2022
Statut: ppublish

Résumé

Background Peripheral artery disease is endemic in our globally aging population, with >200 million affected worldwide. Graft/stent thrombosis after revascularization is common and frequently results in amputation, major adverse cardiovascular events, and cardiovascular mortality. Optimizing medications to decrease thrombosis is of paramount importance; however, limited guidance exists on how to use and monitor antithrombotic therapy in this heterogeneous population. Thromboelastography with platelet mapping (TEG-PM) provides comprehensive coagulation metrics and may be integral to the next stage of patient-centered thrombophrophylaxis. This prospective study aimed to determine if TEG-PM could predict subacute graft/stent thrombosis following lower extremity revascularization, and if objective cut point values could be established to identify those high-risk patients. Methods and Results We conducted a single-center prospective observational study of patients undergoing lower extremity revascularization. Patients were followed up for the composite end point postoperative graft/stent thrombosis at 1 year. TEG-PM analysis of the time point before thrombosis in the event group was compared with the last postoperative visit in the nonevent group. Cox proportional hazards analysis examined the association of TEG-PM metrics to thrombosis. Cut point analysis explored the predictive capacity of TEG-PM metrics for those at high risk. A total of 162 patients were analyzed, of whom 30 (18.5%) experienced graft/stent thrombosis. Patients with thrombosis had significantly greater platelet aggregation (79.7±15.7 versus 58.5±26.4) and lower platelet inhibition (20.7±15.6% versus 41.1±26.6%) (all

Identifiants

pubmed: 36565191
doi: 10.1161/JAHA.122.027790
pmc: PMC9973575
doi:

Substances chimiques

Platelet Aggregation Inhibitors 0

Types de publication

Observational Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e027790

Subventions

Organisme : NIA NIH HHS
ID : R21 AG077310
Pays : United States

Références

Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
Eur Heart J. 2010 Jan;31(1):17-28
pubmed: 19948715
Med Princ Pract. 2018;27(4):356-361
pubmed: 29754149
J Vasc Surg. 2010 Oct;52(4):825-33, 833.e1-2
pubmed: 20678878
Surgery. 1984 Sep;96(3):462-6
pubmed: 6474351
JAMA Surg. 2015 Jan;150(1):84-6
pubmed: 25409197
J Am Coll Cardiol. 2018 May 22;71(20):2306-2315
pubmed: 29540326
Lancet. 2000 Jan 29;355(9201):346-51
pubmed: 10665553
Curr Pharm Des. 2018;24(38):4554-4557
pubmed: 30621557
J Trauma Acute Care Surg. 2020 Dec;89(6):999-1017
pubmed: 32941349
Eur J Vasc Endovasc Surg. 2003 Jan;25(1):16-22
pubmed: 12525806
Am J Med. 2012 Sep;125(9):882-7.e1
pubmed: 22748400
Semin Vasc Surg. 2022 Jun;35(2):124-131
pubmed: 35672102
Blood. 2007 Mar 15;109(6):2285-92
pubmed: 17148593
Eur J Vasc Endovasc Surg. 2013 Jul;46(1):124-31
pubmed: 23628328
J Vasc Surg. 2022 Mar;75(3):1107-1115
pubmed: 34788649
Circulation. 2017 Mar 21;135(12):e726-e779
pubmed: 27840333
Circulation. 2013 Apr 9;127(14):1522-9, 1529e1-6
pubmed: 23501976
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Atherosclerosis. 2018 Aug;275:379-381
pubmed: 29843915
Thorac Cardiovasc Surg. 2003 Apr;51(2):67-72
pubmed: 12730813
Lancet. 2016 Oct 22;388(10055):2015-2022
pubmed: 27581531
J Am Coll Cardiol. 2018 May 29;71(21):2450-2467
pubmed: 29793635
Circulation. 2011 Sep 6;124(10):1132-7
pubmed: 21875913
Shock. 2013 Jan;39(1):45-9
pubmed: 23247121
J Vasc Surg. 2017 Nov;66(5):1576-1586
pubmed: 28893489
JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28
pubmed: 24262612
World J Cardiol. 2010 Jun 26;2(6):131-4
pubmed: 21160730
J Vasc Surg. 2018 Jul;68(1):256-284
pubmed: 29937033
N Engl J Med. 2020 May 21;382(21):1994-2004
pubmed: 32222135
Vasc Med. 2008 Feb;13(1):63-74
pubmed: 18372442
Arch Intern Med. 2008 Nov 24;168(21):2377-81
pubmed: 19029504
Ann Vasc Surg. 2022 Nov;87:213-224
pubmed: 35339591
Glob Cardiol Sci Pract. 2013 Nov 01;2013(2):130-2
pubmed: 24689011
J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73
pubmed: 24076493

Auteurs

Monica Majumdar (M)

Division of Vascular and Endovascular Surgery, Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston MA.

Ryan P Hall (RP)

Division of Vascular and Endovascular Surgery, Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston MA.

Zachary Feldman (Z)

Division of Vascular and Endovascular Surgery, Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston MA.

Guillaume Goudot (G)

Cardiovascular Research Center, Division of Cardiology Massachusetts General Hospital/Harvard Medical School Boston MA.

Natalie Sumetsky (N)

Department of Epidemiology and Statistics University of Pittsburg PA.

Samuel Jessula (S)

Division of Vascular and Endovascular Surgery, Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston MA.

Amanda Kirshkaln (A)

Division of Vascular and Endovascular Surgery, Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston MA.

Tiffany Bellomo (T)

Division of Vascular and Endovascular Surgery, Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston MA.

David Chang (D)

Healthcare Research and Policy Development, Codman Center, Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston MA.

Jessica Cardenas (J)

Center for Translational Injury Research University of Texas-Houston Houston TX.

Rushad Patell (R)

Division of Hematology/Oncology Beth Israel Deaconess Medical Center/Harvard Medical School Boston MA.

Matthew Eagleton (M)

Division of Vascular and Endovascular Surgery, Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston MA.

Anahita Dua (A)

Division of Vascular and Endovascular Surgery, Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH